Clinical Trial Detail

NCT ID NCT03716180
Title DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Dana-Farber Cancer Institute
Indications

Her2-receptor positive breast cancer

Therapies

Paclitaxel + Pertuzumab + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST